Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

Stock Information for Solid Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Solid Biosciences Inc.

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.